Double encapsulated oral transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota
APHP180583
Phase 3 small_molecule active
Quick answer
Double encapsulated oral transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota for Severe Irritable Bowel Syndrome (IBS) is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Severe Irritable Bowel Syndrome (IBS)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active